Ben Tranchina

Ben Tranchina joined Nuvectra in August of 2018. He has more than 25 years of experience in technology business leadership in both early-stage and multi-national commercial companies and holds approximately 30 issued or pending patents relevant to neuromodulation. Prior to joining Nuvectra as Chief Technical Operations Officer, Mr. Tranchina served as the Chief Technology Officer for Neurotechnology Innovations Translator (NIT) LLC, a privately held company in Columbus, Ohio, which develops and commercializes neurotechnology solutions. During his tenure at NIT, Mr. Tranchina also served as CEO for NIT portfolio company Veressa Medical where he led the development of an innovative peripheral nerve stimulation system for the treatment of pelvic floor dysfunction and peripheral pain. Before that, Mr. Tranchina served in various leadership roles and as VP of Research and Development for ten years at St. Jude Medical’s (SJM) Neuromodulation Division and Advanced Neuromodulation Systems, Inc. (ANSI), a company acquired by St. Jude Medical, Inc., in 2005. During his time at SJM, Mr. Tranchina’s teams launched nine first-to-market products, and, as a result, he was awarded SJM’s Neuromodulation Inventor of the Year award. Mr. Tranchina holds a B.S. and a M.S. in Electrical Engineering from the University of Texas at Dallas, specializing in Microelectronic Circuits and Systems.